DrugPatentWatch Database Preview

Details for Patent: 7,776,895

« Back to Dashboard

Which drugs does patent 7,776,895 protect, and when does it expire?

Patent 7,776,895 protects ANORO ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in three NDAs.

This patent has fifty-three patent family members in thirty countries.

Summary for Patent: 7,776,895

Title:	Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Abstract:	The invention provides inhalation devices comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol; or a salt or solvate thereof, inhalation devices comprising formulations and combinations of the compound or a salt or solvate thereof, and methods for the treatment or prophylaxis of a clinical condition in a mammal by employing the inhalation devices.
Inventor(s):	Box; Philip Charles (Stevenage, GB), Coe; Diane Mary (Stevenage, GB), Looker; Brian Edgar (Stevenage, GB), Mann; Inderjit Singh (Stevenage, GB), Procopiou; Panayiotis Alexandrou (Stevenage, GB)
Assignee:	Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:	12/211,322
Patent Claim Types: see list of patent claims	Formulation; Compound; Delivery;

Drugs Protected by US Patent 7,776,895

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes			Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013		RX	Yes	Yes			Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes			Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes			Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 7,776,895

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0122201.7	Sep 14, 2001
United Kingdom	0126997.6	Nov 09, 2001

International Family Members for US Patent 7,776,895

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	036874
Argentina	091595
Austria	417606
Australia	2002326026
Brazil	0212455